Mike Burgess named head of oncology discovery translational area at Roche
This article was originally published in Scrip
Roche has named Dr Mike Burgess head of the oncology discovery and translational area (DTA). The oncology DTA, which is one of five disease-focused organisations at Roche, is part of the pharma research and early development (pRED) organisation, which oversees research, and early- to late-stage development in oncology. Dr Burgess was most recently head of academic alliances (part of pRED Development). He joined Roche from Lilly in 2006 as clinical research and licensing liaison, oncology, for Roche Products. In May 2008, he became the European Head of Roche’s clinical research early development unit in its oncology franchise.
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.